Expertise in

conditions

Dr. Anuj C. Malik

Infectious Disease

Office

3193 Howell Mill Rd NW Ste 125,

Atlanta, GA

Accepting New Patients

Expertise in

conditions

Office

3193 Howell Mill Rd NW Ste 125,

Atlanta, GA

Overview

Anuj Malik is an Infectious Disease provider practicing medicine in Atlanta, Georgia.

Dr. Malik is highly rated in 4 conditions, according to our data. His clinical expertise encompasses COVID-19, Multisystem Inflammatory Syndrome in Children (MIS-C), Pneumonia, and Severe Acute Respiratory Syndrome (SARS).

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 6 clinical trials. Dr. Malik is currently accepting new patients.

Specialties

Infectious Disease

Licenses

Internal Medicine in OK

Hospital Affiliations

Ascension St John Medical Center

Languages Spoken

English

Hindi

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Alliant Health

Anthem BCBS

AvMed

Baylor Scott & White Health

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
OTHER COMMERCIAL

Blue Cross Blue Shield

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Cambia Health Solutions

EPO
INSURANCE PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL
OTHER MEDICARE
PPO

Capital Blue Cross

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
OTHER MEDICARE PART D
PPO

CareFirst

CareSource

Cigna

Community Health Choice

HMO
MANAGED MEDICAID PLAN
MEDICARE SNP

CommunityCare

Cook Children's Health Plan

MANAGED MEDICAID PLAN

Devoted Health

MEDICARE MAPD
OTHER MEDICARE

EmblemHealth

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL
OTHER MEDICARE PART D

Health Alliance

Health Care Services Corporation

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark

Horizon Healthcare

Humana

HMO
INDEMNITY
POS
PPO

Inland Empire Health Plan

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE

Kaiser Permanente

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER MEDICARE
POS
PPO

Managed Medicaid

OTHER MANAGED MEDICAID

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

Medicare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE PART D

Oscar

Piedmont

Premera Blue Cross

INSURANCE PLAN
MEDICARE MAPD
OTHER COMMERCIAL
PPO

Santa Clara Family Health Plan

MANAGED MEDICAID PLAN
MEDICARE SNP
MEDICARE-MEDICAID PLAN

SCAN Health Plan

INSURANCE PLAN
MEDICARE MAPD

SelectHealth

Spectrum Priority Health

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
OTHER COMMERCIAL

Superior Health Plan

MANAGED MEDICAID PLAN
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL

Trustmark

UnitedHealthcare

Valley Health

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 36 Less Insurance Carriers -

Locations

Office
3193 Howell Mill Rd NW Ste 125, Atlanta, GA 30327

Call: 800-400-6354

Other Locations

Oklahoma Oncology Inc
1705 E 19th St Ste 201, Tulsa, OK 74104

Call: 918-403-7100

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Varespladib in Patients Hospitalized With Severe COVID 19 Caused by SARS-CoV-2

Enrollment Status: Terminated

Publish Date: May 15, 2025

Intervention Type: Drug

Study Drug: Varespladib

Study Phase: Phase 2

A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness